Format

Send to

Choose Destination
Br J Cancer. 2014 Jun 10;110(12):2905-13. doi: 10.1038/bjc.2014.252. Epub 2014 May 22.

Cdc20 and securin overexpression predict short-term breast cancer survival.

Author information

1
Department of Pathology, University of Turku and Turku University Central Hospital, Turku, Finland.
2
Department of Medical Statistics, Medical Faculty, University of Turku, Turku, Finland.
3
Department of Pathology, Jyväskylä Central Hospital, Jyväskylä, Finland.

Abstract

BACKGROUND:

Cdc20 is an essential component of cell division and responsible for anaphase initiation regulated by securin degradation. Cdc20 function is strongly regulated by the spindle assembly checkpoint to ensure the timely separation of sister chromatids and integrity of the genome. We present the first results on Cdc20 in a large clinical breast cancer material.

METHODS:

The study was based on 445 breast cancer patients with up to 20 years of follow-up (mean 10.0 years). DNA content was determined by image cytometry on cell imprints, and Cdc20 and securin immunohistochemistry on tissue microarrays of breast cancer tissue.

RESULTS:

In our results, high Cdc20 and securin expression was associated with aneuploid DNA content. In prognostic analyses, high Cdc20 immunoexpression alone and in combination with high securin immunoexpression indicated aggressive course of disease and up to 6.8-fold (P<0.001) risk of breast cancer death. Particularly, high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer (TNBC) subtype.

CONCLUSIONS:

We report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.

PMID:
24853182
PMCID:
PMC4056061
DOI:
10.1038/bjc.2014.252
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center